Home Cart Sign in  
Chemical Structure| 875446-37-0 Chemical Structure| 875446-37-0
Chemical Structure| 875446-37-0

Anacetrapib

CAS No.: 875446-37-0

Anacetrapib is a potent, selective, reversible rhCETP and mutantCETP (C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure.

Synonyms: MK-0859

4.5 *For Research Use Only !

Cat. No.: A293882 Purity: 98%

Change View

Size Price

USA Stock *0-1 Day

Global Stock *5-7 Days

In Stock
1mg łÇò¶ÊÊ Inquiry Inquiry
2mg łËʶÊÊ Inquiry Inquiry
5mg łËͶÊÊ Inquiry Inquiry
10mg łËî¶ÊÊ Inquiry Inquiry
25mg ł§ÿ¶ÊÊ Inquiry Inquiry
50mg łÍ˶ÊÊ Inquiry Inquiry
100mg łÿǶÊÊ Inquiry Inquiry
250mg łò˶ÊÊ Inquiry Inquiry

  • 1mg

    łÇò¶ÊÊ

  • 2mg

    łËʶÊÊ

  • 5mg

    łËͶÊÊ

  • 10mg

    łËî¶ÊÊ

  • 25mg

    ł§ÿ¶ÊÊ

  • 50mg

    łÍ˶ÊÊ

  • 100mg

    łÿǶÊÊ

  • 250mg

    łò˶ÊÊ

In Stock

- +

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of [ Anacetrapib ]

CAS No. :875446-37-0
Formula : C30H25F10NO3
M.W : 637.51
SMILES Code : O=C1O[C@H](C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)[C@H](C)N1CC3=CC(C(F)(F)F)=CC=C3C4=CC(C(C)C)=C(F)C=C4OC
Synonyms :
MK-0859
MDL No. :MFCD16294903

Safety of [ Anacetrapib ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • CETP

    rhCETP, IC50:7.9 nM

    Mutant CETP (C13S), IC50:11.8 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00565006 Ambulatory Blood Pressure Phase 1 Completed - -
NCT00565292 Hypercholesterolemia ... More >> Hyperlipidemia Less << Phase 1 Completed - -
NCT00325455 Hypercholesterolemia ... More >> Mixed Hyperlipemia Less << Phase 2 Terminated - -
NCT00977288 Dyslipidemia Phase 2 Completed - -
NCT00990808 Dyslipidemia Phase 1 Completed - -
NCT00685776 Coronary Heart Disease (CHD) ... More >> CHD Risk-Equivalent Disease Less << Phase 3 Completed - -
NCT02931188 - Completed - United Kingdom ... More >> Clinical Investigation Ward, Addenbrooke's Hospital Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ Less <<
NCT01524289 Hyperlipoproteinemia Type II ... More >> Heterozygous Familial Hypercholesterolemia Less << Phase 3 Active, not recruiting November 30, 2018 -
NCT01114490 Dyslipidemia Phase 1 Completed - -
NCT01717300 Hypercholesterolemia Phase 3 Completed - -
NCT01252953 Atherosclerotic Cardiovascular... More >> Disease Less << Phase 3 Active, not recruiting April 2019 United Kingdom ... More >> CTSU, University of Oxford Oxford, Oxfordshire, United Kingdom, OX3 7LF Less <<
NCT01760460 Dyslipidemia Phase 3 Completed - -
NCT01860729 Hypercholesterolemia Phase 3 Completed - -
NCT01252953 - Active, not recruiting - -
NCT01122667 Dyslipidemia Phase 1 Completed - -
NCT01841684 Hyperlipoproteinemia Type II ... More >> Homozygous Familial Hypercholesterolemia Less << Phase 3 Terminated - -
NCT01824238 Heterozygous Familial Hypercho... More >>lesterolemia (HeFH) Less << Phase 3 Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.57mL

0.31mL

0.16mL

7.84mL

1.57mL

0.78mL

15.69mL

3.14mL

1.57mL

References

 

Historical Records

Categories